Zhejiang Starry Pharm Co Ltd Asset Resilience Ratio
Zhejiang Starry Pharm Co Ltd asset resilience ratio. Zhejiang Starry Pharm Co Ltd (603520) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Zhejiang Starry Pharm Co Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Zhejiang Starry Pharm Co Ltd (2016–2023)
Asset resilience ratio of Zhejiang Starry Pharm Co Ltd from 2016 to 2023. This chart shows how Zhejiang Starry Pharm Co Ltd's Asset Resilience Ratio has changed over time. Read 603520 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Zhejiang Starry Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Zhejiang Starry Pharm Co Ltd (603520) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥23.15K | 0.0% |
| Total Liquid Assets | CN¥23.15K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Zhejiang Starry Pharm Co Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhejiang Starry Pharm Co Ltd Industry Peers by Asset Resilience Ratio
Compare Zhejiang Starry Pharm Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
Zhejiang Starry Pharm Co Ltd Asset Resilience Ratio by Year (2016–2023)
Zhejiang Starry Pharm Co Ltd asset resilience ratio by year from 2016 to 2023. The table below shows the annual Asset Resilience Ratio data for Zhejiang Starry Pharm Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | CN¥23.15K ≈ $3.39K |
CN¥5.52 Billion ≈ $807.23 Million |
-0.02pp |
| 2022-12-31 | 0.02% | CN¥876.69K ≈ $128.29K |
CN¥5.30 Billion ≈ $775.88 Million |
-1.42pp |
| 2021-12-31 | 1.43% | CN¥70.16 Million ≈ $10.27 Million |
CN¥4.90 Billion ≈ $716.35 Million |
-1.53pp |
| 2020-12-31 | 2.97% | CN¥130.76 Million ≈ $19.13 Million |
CN¥4.41 Billion ≈ $644.79 Million |
+2.47pp |
| 2017-12-31 | 0.50% | CN¥10.00 Million ≈ $1.46 Million |
CN¥2.01 Billion ≈ $294.62 Million |
-3.20pp |
| 2016-12-31 | 3.70% | CN¥70.00 Million ≈ $10.24 Million |
CN¥1.89 Billion ≈ $277.08 Million |
-- |
About Zhejiang Starry Pharm Co Ltd
Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical raw materials in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iomeprol, ioversol, and gadoben… Read more